Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-alpha in systemic lupus erythematosus.

Mary K Crow1, Kyriakos A Kirou

  • 1Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA. crowm@hss.edu

Current Opinion in Rheumatology
|August 18, 2004
PubMed
Summary

Interferon-alpha (IFNalpha) plays a key role in systemic lupus erythematosus (SLE) pathogenesis. Evidence shows elevated IFNalpha levels and its induction of SLE-like symptoms, suggesting it as a therapeutic target.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An NT5E loss-of-function variant permits tissue inflammation and hypertension in systemic lupus erythematosus.

iScience·2026
Same author

Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial.

Annals of the rheumatic diseases·2026
Same author

Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus.

Current rheumatology reports·2026
Same author

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025.

Annals of the rheumatic diseases·2026
Same author

New developments and future directions in the management of systemic lupus erythematosus.

Current opinion in immunology·2026
Same author

Renal Replacement Therapy in Lupus Nephritis-Related End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.

ACR open rheumatology·2025

Area of Science:

  • Immunology
  • Autoimmunity
  • Molecular Biology

Background:

  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease.
  • Interferon-alpha (IFNalpha) has been implicated in SLE pathogenesis for decades.
  • Elevated IFNalpha levels are frequently observed in SLE patients.

Purpose of the Study:

  • To review evidence linking interferon-alpha (IFNalpha) to systemic lupus erythematosus (SLE) pathogenesis.
  • To explore mechanisms by which IFNalpha contributes to SLE autoimmunity and immune dysfunction.

Main Methods:

  • Review of existing clinical and experimental data.
  • Analysis of gene expression in SLE patient cells.
  • Investigation of IFNalpha induction mechanisms.

Related Experiment Videos

Main Results:

  • IFNalpha administration can induce SLE-like symptoms.
  • IFNalpha-regulated genes are upregulated in SLE peripheral blood cells.
  • Immune complexes and Toll-like receptors (TLRs) contribute to IFNalpha production.

Conclusions:

  • Strong evidence supports a significant role for IFNalpha in SLE pathogenesis.
  • The IFNalpha pathway is a potential therapeutic target for SLE treatment.